At EuroMed Foundation, we make it a priority to track promising science in the industry, and there’s been some exciting news over the past several months when it comes to alternative cancer therapies. A pair of clinical trials has shown impressive results for treating leukemia by genetically tweaking patients’ own blood cells.
According to a recent article in The Wall Street Journal, the cancer therapies involve removing a patient’s white blood cells, known as T-cells. Researchers genetically alter the T-cells, programming them with a disabled virus to produce receptors that target malignant proteins. The researchers inject these T-cells back into the patient’s body, where they go to work attacking the cancer from the inside.
This treatment is a form of “immunotherapy,” because it harnesses the body’s natural defenses to fight disease. In this case, researchers enhance the body’s natural response with genetic modification of cells.
We at EuroMed also use immunotherapies to help our patients fight cancer. Our treatments involve supporting the immune system through detoxification and good nutrition so a patient can better fight off cancer with only low doses of chemotherapy.
The Wall Street Journal points out that the T-cell treatment faces some major hurdles — namely involving cost — before it can reach widespread success. Nonetheless, our doctors are pleased to see such strides being made and such attention being paid to this alternative approach to traditional cancer treatment. We believe patients best fight off cancer when their bodies are made healthier, rather than harmed by the deleterious effects of chemotherapy and radiation. We plan to keep an eye on these promising advances in immunotherapy in the hopes that gentler, more supportive treatment someday becomes the norm.